Aldeyra Therapeutics, Inc.
ALDX
$1.51
-$0.03-1.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -18.17% | -33.81% | -19.26% | -21.78% | -3.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.86% | -53.58% | -41.34% | -8.99% | 23.84% |
| Operating Income | 54.86% | 53.58% | 41.34% | 8.99% | -23.84% |
| Income Before Tax | 54.46% | 52.56% | 39.40% | 3.58% | -33.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.46% | 52.56% | 39.40% | 3.58% | -33.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.46% | 52.56% | 39.40% | 3.58% | -33.67% |
| EBIT | 54.86% | 53.58% | 41.34% | 8.99% | -23.84% |
| EBITDA | 55.15% | 53.81% | 41.52% | 9.03% | -23.99% |
| EPS Basic | 54.83% | 53.00% | 39.94% | 4.26% | -32.72% |
| Normalized Basic EPS | 54.83% | 53.00% | 39.95% | 4.27% | -32.75% |
| EPS Diluted | 54.83% | 53.00% | 39.94% | 4.26% | -32.72% |
| Normalized Diluted EPS | 54.83% | 53.00% | 39.95% | 4.27% | -32.75% |
| Average Basic Shares Outstanding | 0.79% | 0.94% | 0.96% | 0.88% | 0.85% |
| Average Diluted Shares Outstanding | 0.79% | 0.94% | 0.96% | 0.88% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |